Overexpression of CD24, c-myc and phospholipase 2A in prostate cancer tissue samples obtained by needle biopsy

B. Nagy, Attila Szendroi, I. Romics

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Altered CD24, c-myc and phospholipase 2a expression was reported in different cancers. Our aim was to measure the expression of these genes in prostate cancer tissues, and compare it to non-cancerous samples. Prostate tissue samples were collected by needle biopsy from 20 prostate cancer (PCA) and 11 benign prostate hyperplasic (BPH) patients. RNA was isolated; cDNA synthetized, CD24, c-myc and phospholipase 2A (PL2A) expressions were determined by quantitative real-time PCR method. The expression of β-globin gene was measured for normalization of the gene expression results. Serum prostate specific antigen (PSA) levels were determined by microparticle enzyme immunoassay (MEIA) method. PSA levels were significantly different between the PCA and BPH groups, 252.37±308.33 ng/ml vs. 3.5±2.14 ng/ml (p=0.001), respectively. CD24 expression was 988.86±3041 ng/μl in prostate tumor and 4.00±4.25 ng/μl in the BPH group (p=0.035). The c-myc expression was 88.32±11.93 ng/μl in the prostate tumor and 17.08±21.75 ng/μl in the BPH group (p=0.02), and the PL2A 31.36±67.02 ng/μl was in PCA and 5.56±14.08 ng/μl in BPH (p=0.025). Gleason's scores showed correlation with c-myc (p=0.019) and PSA (p=0.033) levels. Overexpression of PL2A, CD24 and c-myc was observed in prostate cancer samples using quantitative real-time PCR method.

Original languageEnglish
Pages (from-to)279-283
Number of pages5
JournalPathology and Oncology Research
Volume15
Issue number2
DOIs
Publication statusPublished - Jun 2009

Fingerprint

Phospholipases
Needle Biopsy
Prostate
Prostatic Neoplasms
Prostate-Specific Antigen
Gene Expression
Real-Time Polymerase Chain Reaction
Neoplasms
Globins
Neoplasm Grading
Immunoenzyme Techniques
Complementary DNA
RNA
Serum

Keywords

  • C-myc
  • CD24
  • Gene expression
  • Phospholipase 2A
  • Prostate cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pathology and Forensic Medicine

Cite this

Overexpression of CD24, c-myc and phospholipase 2A in prostate cancer tissue samples obtained by needle biopsy. / Nagy, B.; Szendroi, Attila; Romics, I.

In: Pathology and Oncology Research, Vol. 15, No. 2, 06.2009, p. 279-283.

Research output: Contribution to journalArticle

@article{f88349a715ee47ecac518e97f5c09dfa,
title = "Overexpression of CD24, c-myc and phospholipase 2A in prostate cancer tissue samples obtained by needle biopsy",
abstract = "Altered CD24, c-myc and phospholipase 2a expression was reported in different cancers. Our aim was to measure the expression of these genes in prostate cancer tissues, and compare it to non-cancerous samples. Prostate tissue samples were collected by needle biopsy from 20 prostate cancer (PCA) and 11 benign prostate hyperplasic (BPH) patients. RNA was isolated; cDNA synthetized, CD24, c-myc and phospholipase 2A (PL2A) expressions were determined by quantitative real-time PCR method. The expression of β-globin gene was measured for normalization of the gene expression results. Serum prostate specific antigen (PSA) levels were determined by microparticle enzyme immunoassay (MEIA) method. PSA levels were significantly different between the PCA and BPH groups, 252.37±308.33 ng/ml vs. 3.5±2.14 ng/ml (p=0.001), respectively. CD24 expression was 988.86±3041 ng/μl in prostate tumor and 4.00±4.25 ng/μl in the BPH group (p=0.035). The c-myc expression was 88.32±11.93 ng/μl in the prostate tumor and 17.08±21.75 ng/μl in the BPH group (p=0.02), and the PL2A 31.36±67.02 ng/μl was in PCA and 5.56±14.08 ng/μl in BPH (p=0.025). Gleason's scores showed correlation with c-myc (p=0.019) and PSA (p=0.033) levels. Overexpression of PL2A, CD24 and c-myc was observed in prostate cancer samples using quantitative real-time PCR method.",
keywords = "C-myc, CD24, Gene expression, Phospholipase 2A, Prostate cancer",
author = "B. Nagy and Attila Szendroi and I. Romics",
year = "2009",
month = "6",
doi = "10.1007/s12253-008-9077-1",
language = "English",
volume = "15",
pages = "279--283",
journal = "Pathology and Oncology Research",
issn = "1219-4956",
publisher = "Springer Netherlands",
number = "2",

}

TY - JOUR

T1 - Overexpression of CD24, c-myc and phospholipase 2A in prostate cancer tissue samples obtained by needle biopsy

AU - Nagy, B.

AU - Szendroi, Attila

AU - Romics, I.

PY - 2009/6

Y1 - 2009/6

N2 - Altered CD24, c-myc and phospholipase 2a expression was reported in different cancers. Our aim was to measure the expression of these genes in prostate cancer tissues, and compare it to non-cancerous samples. Prostate tissue samples were collected by needle biopsy from 20 prostate cancer (PCA) and 11 benign prostate hyperplasic (BPH) patients. RNA was isolated; cDNA synthetized, CD24, c-myc and phospholipase 2A (PL2A) expressions were determined by quantitative real-time PCR method. The expression of β-globin gene was measured for normalization of the gene expression results. Serum prostate specific antigen (PSA) levels were determined by microparticle enzyme immunoassay (MEIA) method. PSA levels were significantly different between the PCA and BPH groups, 252.37±308.33 ng/ml vs. 3.5±2.14 ng/ml (p=0.001), respectively. CD24 expression was 988.86±3041 ng/μl in prostate tumor and 4.00±4.25 ng/μl in the BPH group (p=0.035). The c-myc expression was 88.32±11.93 ng/μl in the prostate tumor and 17.08±21.75 ng/μl in the BPH group (p=0.02), and the PL2A 31.36±67.02 ng/μl was in PCA and 5.56±14.08 ng/μl in BPH (p=0.025). Gleason's scores showed correlation with c-myc (p=0.019) and PSA (p=0.033) levels. Overexpression of PL2A, CD24 and c-myc was observed in prostate cancer samples using quantitative real-time PCR method.

AB - Altered CD24, c-myc and phospholipase 2a expression was reported in different cancers. Our aim was to measure the expression of these genes in prostate cancer tissues, and compare it to non-cancerous samples. Prostate tissue samples were collected by needle biopsy from 20 prostate cancer (PCA) and 11 benign prostate hyperplasic (BPH) patients. RNA was isolated; cDNA synthetized, CD24, c-myc and phospholipase 2A (PL2A) expressions were determined by quantitative real-time PCR method. The expression of β-globin gene was measured for normalization of the gene expression results. Serum prostate specific antigen (PSA) levels were determined by microparticle enzyme immunoassay (MEIA) method. PSA levels were significantly different between the PCA and BPH groups, 252.37±308.33 ng/ml vs. 3.5±2.14 ng/ml (p=0.001), respectively. CD24 expression was 988.86±3041 ng/μl in prostate tumor and 4.00±4.25 ng/μl in the BPH group (p=0.035). The c-myc expression was 88.32±11.93 ng/μl in the prostate tumor and 17.08±21.75 ng/μl in the BPH group (p=0.02), and the PL2A 31.36±67.02 ng/μl was in PCA and 5.56±14.08 ng/μl in BPH (p=0.025). Gleason's scores showed correlation with c-myc (p=0.019) and PSA (p=0.033) levels. Overexpression of PL2A, CD24 and c-myc was observed in prostate cancer samples using quantitative real-time PCR method.

KW - C-myc

KW - CD24

KW - Gene expression

KW - Phospholipase 2A

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=68949125382&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68949125382&partnerID=8YFLogxK

U2 - 10.1007/s12253-008-9077-1

DO - 10.1007/s12253-008-9077-1

M3 - Article

C2 - 18752058

AN - SCOPUS:68949125382

VL - 15

SP - 279

EP - 283

JO - Pathology and Oncology Research

JF - Pathology and Oncology Research

SN - 1219-4956

IS - 2

ER -